FDA Peptide Update: Category 2 Removals Explained The Sikiric Problem: One Lab, Thirty Years, Zero Trials That Matter The reason peptide access is changing comes down to two regulatory categories most patients don't know exist: 503A and 503B. 503A = traditional compounding pharmacies. State licensed, patient specific prescriptions. 503B = FDA registered outsourcing The FDA didn't bring peptides back. It opened a formal docket. And that distinction matters. This is not a blanket approval. Not a wellness free for all. Not one announcement that changes everything overnight. Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy FDA Peptide Reclassification 2026: What It Means for Providers